ENTERA BIO LTD.
(Registrant)
|
|||
By:
|
/s/Adam Gridley
|
||
Name: Adam Gridley
|
|||
Title: Chief Executive Officer
|
|||
Page
|
|
CONDENSED CONSOLIDTED FINANCIAL STATEMENTS (Unaudited) – U.S DOLLARS IN THOUSANDS ($):
|
|
2
|
|
3
|
|
4-5
|
|
6-7
|
|
8-16
|
September 30
|
December 31
|
|||||||
2019
|
2018
|
|||||||
U.S. dollars in thousands
|
||||||||
A s s e t s
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
5,907
|
7,506
|
||||||
Short-term bank deposits
|
-
|
4,015
|
||||||
Accounts receivable
|
-
|
725
|
||||||
Other current assets
|
297
|
220
|
||||||
TOTAL CURRENT ASSETS
|
6,204
|
12,466
|
||||||
NON-CURRENT ASSETS:
|
||||||||
Property and equipment
|
217
|
224
|
||||||
Right to use assets
|
295
|
-
|
||||||
Intangible assets
|
607
|
651
|
||||||
TOTAL NON-CURRENT ASSETS
|
1,119
|
875
|
||||||
TOTAL ASSETS
|
7,323
|
13,341
|
||||||
Liabilities and shareholders' equity
|
||||||||
CURRENT LIABILITIES:
|
||||||||
Accounts payable:
|
||||||||
Trade
|
594
|
473
|
||||||
Other
|
1,501
|
1,090
|
||||||
Lease liabilities
|
156
|
-
|
||||||
Contract liabilities
|
91
|
225
|
||||||
TOTAL CURRENT LIABILITIES
|
2,342
|
1,788
|
||||||
NON-CURRENT LIABILITIES:
|
||||||||
Warrants to purchase ordinary shares
|
700
|
1,372
|
||||||
Lease liabilities
|
173
|
-
|
||||||
Severance pay obligations, net
|
70
|
65
|
||||||
TOTAL NON-CURRENT LIABILITIES
|
943
|
1,437
|
||||||
TOTAL LIABILITIES
|
3,285
|
3,225
|
||||||
COMMITMENTS AND CONTINGENCIES
|
||||||||
SHAREHOLDERS' EQUITY:
|
||||||||
Ordinary Shares, NIS 0.0000769 par value:
|
||||||||
Authorized - as of September 30, 2019 and December 31, 2018, 140,010,000 shares; issued and outstanding: as of September 30, 2019, and December 31, 2018 – 12,153,980
shares and 11,459,780 shares, respectively.
|
*
|
*
|
||||||
Accumulated other comprehensive income
|
41
|
41
|
||||||
Other reserves
|
11,912
|
13,019
|
||||||
Additional paid in capital
|
51,557
|
49,173
|
||||||
Accumulated deficit
|
(59,472
|
)
|
(52,117
|
)
|
||||
TOTAL SHAREHOLDERS' EQUITY
|
4,038
|
10,116
|
||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
|
7,323
|
13,341
|
Nine months ended
|
Three months ended
|
|||||||||||||||
September 30
|
September 30
|
|||||||||||||||
2019
|
2018
|
2019
|
2018
|
|||||||||||||
U.S. dollars in thousands
|
||||||||||||||||
REVENUE
|
(134
|
)
|
-
|
(60
|
)
|
-
|
||||||||||
COST OF REVENUE
|
102
|
-
|
40
|
-
|
||||||||||||
RESEARCH AND DEVELOPMENT EXPENSES, NET
|
5,234
|
6,464
|
1,786
|
1,806
|
||||||||||||
GENERAL AND ADMINISTRATIVE EXPENSES
|
2,757
|
1,914
|
1,073
|
1,060
|
||||||||||||
OPERATING LOSS
|
7,959
|
8,378
|
2,839
|
2,866
|
||||||||||||
FINANCIAL EXPENSES (INCOME):
|
||||||||||||||||
Loss (income) from change in fair value of financial
liabilities at fair value |
(672
|
)
|
(719
|
)
|
122
|
2,177
|
||||||||||
Other financial expenses , net
|
68
|
-
|
33
|
23
|
||||||||||||
FINANCIAL EXPENSES (INCOME), net
|
(604
|
)
|
(719
|
)
|
155
|
2,200
|
||||||||||
NET COMPREHENSIVE LOSS FOR THE PERIOD
|
7,355
|
7,659
|
2,994
|
5,066
|
U.S. dollars
|
U.S. dollars
|
|||||||||||||||
LOSS PER ORDINARY SHARE:
|
||||||||||||||||
Basic
|
0.63
|
1.13
|
0.25
|
0.45
|
||||||||||||
Diluted
|
0.63
|
1.14
|
0.25
|
0.45
|
||||||||||||
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:
|
||||||||||||||||
Basic
|
11,750,868
|
6,777,841
|
12,045,115
|
11,277,503
|
||||||||||||
Diluted
|
11,750,868
|
6,825,532
|
12,045,115
|
11,277,503
|
Number of Ordinary Shares
|
Ordinary Shares-Amount
|
Accumulated other comprehensive income
|
Other reserve
|
Additional paid in capital
|
Accumulated deficit
|
Total
|
||||||||||||||||||||||
U.S dollars in thousands
|
||||||||||||||||||||||||||||
BALANCE AT JANUARY 1, 2018
|
4,490,720
|
*
|
41
|
7,361
|
2,853
|
(41,813
|
)
|
(31,558
|
)
|
|||||||||||||||||||
CHANGES FOR NINE MONTHS ENDED SEPTEMBER 30, 2018:
|
||||||||||||||||||||||||||||
Net loss for the period
|
-
|
-
|
-
|
-
|
-
|
(7,659
|
)
|
(7,659
|
)
|
|||||||||||||||||||
Share-based compensation
|
-
|
-
|
-
|
933
|
-
|
-
|
933
|
|||||||||||||||||||||
Issuance of shares and warrants, net
|
1,410,000
|
*
|
-
|
427
|
8,011
|
-
|
8,438
|
|||||||||||||||||||||
Conversion of Preferred shares into Ordinary shares
|
4,905,420
|
*
|
-
|
-
|
32,621
|
-
|
32,621
|
|||||||||||||||||||||
Conversion of convertible loan into Ordinary shares
|
622,180
|
*
|
-
|
-
|
4,138
|
-
|
4,138
|
|||||||||||||||||||||
Conversion of Warrants to purchase preferred shares and shares into Warrants to purchase ordinary shares and shares
|
-
|
-
|
-
|
5,548
|
-
|
-
|
5,548
|
|||||||||||||||||||||
Reclassification due to share-based compensation expired
|
-
|
-
|
-
|
(1,090
|
)
|
1,090
|
-
|
-
|
||||||||||||||||||||
contribution from controlling shareholder
|
-
|
-
|
-
|
(51
|
)
|
51
|
-
|
-
|
||||||||||||||||||||
BALANCE AT SEPTEMBER 30, 2018
|
11,428,320
|
*
|
41
|
13,128
|
48,764
|
(49,472
|
)
|
12,461
|
BALANCE AT JANUARY 1, 2019
|
11,459,780
|
*
|
41
|
13,019
|
49,173
|
(52,117
|
)
|
10,116
|
||||||||||||||||||||
CHANGES FOR NINE MONTHS ENDED SEPTEMBER 30, 2019:
|
||||||||||||||||||||||||||||
Net loss for the period
|
-
|
-
|
-
|
-
|
-
|
(7,355
|
)
|
(7,355
|
)
|
|||||||||||||||||||
Issuance of shares due to exercise of
options by employees and consultant |
661,700 |
* |
- |
(586
|
)
|
724 |
- |
138 |
||||||||||||||||||||
Issuance of shares due to exercise of right
to purchase ordinary shares |
32,500 |
* |
- |
(99
|
)
|
199 |
- |
100 |
||||||||||||||||||||
Reclassification due to share-based
compensation and warrants expired |
- |
- |
- |
(1,461
|
)
|
1,461 |
- |
- |
||||||||||||||||||||
Share-based compensation
|
-
|
-
|
-
|
1,039
|
-
|
-
|
1,039
|
|||||||||||||||||||||
BALANCE AT SEPTEMBER 30, 2019
|
12,153,980
|
*
|
41
|
11,912
|
51,557
|
(59,472
|
)
|
4,038
|
Number of Ordinary Shares
|
Ordinary Shares-Amount
|
Accumulated other comprehensive income
|
Other reserve
|
Additional paid in capital
|
Accumulated deficit
|
Total
|
||||||||||||||||||||||
U.S dollars in thousands
|
||||||||||||||||||||||||||||
BALANCE AT JUNE 30, 2018
|
4,490,720
|
*
|
41
|
7,896
|
2,915
|
(44,406
|
)
|
(33,554
|
)
|
|||||||||||||||||||
CHANGES FOR THREE MONTHS ENDED SEPTEMBER 30, 2018:
|
||||||||||||||||||||||||||||
Net loss for the period
|
-
|
-
|
-
|
-
|
-
|
(5,066
|
)
|
(5,066
|
)
|
|||||||||||||||||||
Share-based compensation
|
-
|
-
|
-
|
336
|
-
|
-
|
336
|
|||||||||||||||||||||
Issuance of shares and warrants, net
|
1,410,000
|
*
|
-
|
427
|
8,011
|
-
|
8,438
|
|||||||||||||||||||||
Conversion of Preferred shares into
Ordinary shares |
4,905,420
|
*
|
- |
-
|
32,621
|
- |
32,621
|
|||||||||||||||||||||
Conversion of convertible loan into
Ordinary shares |
622,180
|
* |
- |
-
|
4,138
|
- |
4,138
|
|||||||||||||||||||||
Conversion of Warrants to purchase
preferred shares and shares into Warrants to purchase ordinary shares |
-
|
-
|
- |
5,548
|
-
|
- |
5,548
|
|||||||||||||||||||||
Reclassification due to share-based compensation expired
|
-
|
-
|
-
|
(1,079
|
)
|
1,079
|
-
|
-
|
||||||||||||||||||||
BALANCE AT SEPTEMBER 30, 2018
|
11,428,320
|
*
|
41
|
13,128
|
48,764
|
(49,472
|
)
|
12,461
|
BALANCE AT JUNE 30, 2019
|
11,899,159
|
*
|
41
|
13,563
|
49,342
|
(56,478
|
)
|
6,468
|
||||||||||||||||||||
CHANGES FOR THREE MONTHS
ENDED SEPTEMBER 30, 2019:
|
||||||||||||||||||||||||||||
Net loss for the period
|
-
|
-
|
-
|
-
|
(2,994
|
)
|
(2,994
|
)
|
||||||||||||||||||||
Issuance of shares due to exercise of
options by employees and consultant |
222,321
|
* |
- |
(443
|
)
|
555 |
- |
112 |
||||||||||||||||||||
Reclassification due to share-based
compensation and warrants expired |
- |
- |
- |
(1,461
|
)
|
1,461 |
- |
- |
||||||||||||||||||||
Issuance of shares due to exercise of right
to purchase ordinary shares |
32,500 |
- |
- |
(99
|
)
|
199 |
- |
100 |
||||||||||||||||||||
Share-based compensation
|
-
|
-
|
-
|
352
|
-
|
-
|
352
|
|||||||||||||||||||||
BALANCE AT SEPTEMBER 30, 2019
|
12,153,980
|
*
|
41
|
11,912
|
51,557
|
(59,472
|
)
|
4,038
|
Nine months ended September 30
|
||||||||
2019
|
2018
|
|||||||
(Unaudited)
|
||||||||
U.S dollars in thousands
|
||||||||
CASH FLOWS USED IN OPERATING ACTIVITIES:
|
||||||||
Net loss for the period
|
(7,355
|
)
|
(7,659
|
)
|
||||
Adjustments required to reflect net cash
|
||||||||
used in operating activities (see appendix A)
|
1,640
|
215
|
||||||
Net cash used in operating activities
|
(5,715
|
)
|
(7,444
|
)
|
||||
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:
|
||||||||
Short-term bank deposits
|
4,000
|
|||||||
Purchase of property and equipment
|
(40
|
)
|
(68
|
)
|
||||
Net cash provided by (used in) investing activities
|
3,960
|
(68
|
)
|
|||||
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:
|
||||||||
Principle element of lease payments
|
(82
|
)
|
-
|
|||||
Issuance of ordinary shares and tradable warrants, net of issuance costs
|
9,624
|
|||||||
Proceeds from exercise of warrants
|
100
|
-
|
||||||
Proceeds from exercise of options
|
138
|
-
|
||||||
Net cash provided by financing activities
|
156
|
9,624
|
||||||
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
(1,599
|
)
|
2,112
|
|||||
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD
|
7,506
|
11,746
|
||||||
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD
|
5,907
|
13,858
|
Nine months
ended September 30
|
||||||||
2019
|
2018
|
|||||||
(Unaudited)
|
||||||||
U.S dollars in thousands
|
||||||||
APPENDIX A:
|
||||||||
Adjustments required to reflect net cash used in operating activities:
|
||||||||
Depreciation and amortization
|
185
|
37
|
||||||
Change in fair value of financial liabilities at fair value
|
(672
|
)
|
(719
|
)
|
||||
Financial expenses, net
|
78
|
36
|
||||||
Issuance costs
|
270
|
|||||||
Changes in severance pay obligations, net
|
5
|
(3
|
)
|
|||||
Share-based compensation
|
1,039
|
933
|
||||||
635
|
554
|
|||||||
Changes in working capital:
|
||||||||
Decrease in accounts receivables
|
725
|
-
|
||||||
Increase in other current assets
|
(77
|
)
|
273
|
|||||
Decrease in contract liability
|
(134
|
)
|
-
|
|||||
Increase (decrease) in accounts payable and accruals:
|
||||||||
Trade
|
121
|
(193
|
)
|
|||||
Other
|
411
|
(383
|
)
|
|||||
1,046
|
(303
|
)
|
||||||
Cash used for operating activities -
|
||||||||
Interest paid
|
(41
|
)
|
(36
|
)
|
||||
1,640
|
215
|
APPENDIX B:
|
||||
Supplementary information on financing activities not involving cash flows:
|
||||
Conversion of preferred shares into ordinary shares
|
32,621
|
|||
Conversion of convertible loan into ordinary shares
|
4,138
|
a. |
General:
|
1) |
Entera Bio Ltd. (collectively with its subsidiary, the "Company") was incorporated on September 30, 2009 and commenced operation on June 1, 2010. On January 8, 2018, the Company incorporated Entera Bio Inc., a fully owned subsidiary
based in Delaware USA. The Company is a clinical-stage biopharmaceutical company, focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with
significant unmet medical needs. Currently the Company is focused on the development of oral capsules for the treatment of osteoporosis and hypoparathyroidism. Our lead oral PTH product candidates are EB613 for the treatment of
osteoporosis and EB612 for the treatment of hypoparathyroidism.
|
2) |
Initial Public Offering (IPO)–
|
3) |
Since the Company is engaged in research and development activities, it has not derived significant income from its activities and has incurred accumulated losses in the amount of $59,472 thousand through September 30, 2019 and
negative cashflows from operating activities. As a result of these losses and negative cash flows from operations, along with the Company's current cash position, the Company has sufficient resources to fund its operations through the
middle of the first quarter of 2020. These factors raise substantial doubt as to the Company's ability to continue as a going concern.
|
4) |
On December 10, 2018, the Company entered into a research collaboration and license agreement (the “Amgen Agreement”) with Amgen Inc. (“Amgen”) in inflammatory disease and other serious illnesses. Pursuant to the Amgen Agreement, the
Company and Amgen will use the Company’s proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen also has options to select up to two additional programs
to include in the collaboration. Amgen is responsible for the clinical development, regulatory approval, manufacturing and worldwide commercialization of the programs.
|
b. |
Approval of financial statements
|
a. |
Adjustments recognized on adoption of IFRS 16
The Company has adopted IFRS 16 retrospectively from January 1, 2019 but has not restated comparatives for the 2018 reporting period, as permitted under the specific transitional provisions in the standard. On adoption of IFRS 16, the Company recognized lease liabilities in relation to leases which had previously been classified as “operating leases” under the principles of IAS 17, “Leases”. These liabilities were measured at the present value of the remaining lease payments, discounted using the lessee’s incremental borrowing rate as of January 1, 2019, which was 16%. The remeasurements to the lease liabilities were recognized as adjustments to the related right-of-use assets immediately after the date of initial application. The associated right-of-use assets for facility leases were measured on a retrospective adjusted basis. |
January 1,
2019
|
September 30,
2019
|
|||||||
Facility
|
151
|
288
|
||||||
Vehicles
|
15
|
7
|
||||||
Total right-of-use asset
|
166
|
295
|
|
Payments due by period
|
|||||||||||
|
Total
|
Less than
1 year |
1 - 3 years
|
|||||||||
|
(In thousands)
|
|||||||||||
Operating leases for facility and vehicles as of December 31, 2018
|
$
|
123
|
$
|
87
|
$
|
36
|
||||||
Operating leases for facility and vehicles as of September 30, 2019
|
$
|
389
|
$
|
179
|
$
|
210
|
b. |
Practical expedients applied on adoption of IFRS 16
|
• |
Use of a single discount rate to a portfolio of leases with reasonably similar characteristics;
|
• |
Reliance on previous assessments on whether leases are onerous;
|
• |
Exclusion of initial direct costs for the measurement of the right-of-use asset at the date of initial application;
|
• |
Use of hindsight in determining the lease term where the contract contains options to extend or terminate the lease.
|
c. |
Other information relating to IFRS 16
|
nine months ended
|
Three months ended
|
|||||||
September 30, 2019
|
||||||||
Depreciation expense:
|
||||||||
Facility
|
86
|
31
|
||||||
Vehicles
|
8
|
2
|
||||||
Financial expense
|
41
|
14
|
||||||
Cash paid for amounts included in the measurement of lease liabilities
|
123
|
44
|
||||||
Right of use assets obtained in exchange for new operating lease liabilities
|
223
|
-
|
1) |
Options grants
|
a) |
On January 17, 2019, the Company granted options to purchase 124,000 ordinary shares to certain employees, with an exercise price of $3.97. The options vest over 4 years from the date of grant; 25% will vest on the first anniversary
of the date of grant and the remaining 75% options shall vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of the options at the date of grant was $341 thousand.
|
b) |
On January 17, 2019, the Company's Board of Directors approved to grant options to purchase 25,000 ordinary shares to the CMO, with an exercise price of $3.97. From the total options, 25% will vest on March 1, 2019 and the remaining
75% options shall vest in twelve equal quarterly installments over the next three years starting January 17,2019. The grant was subject to the approval by the shareholders' of the Company, which approved the grant in May 2019. The fair
value of the options at the date of grant was $68 thousand.
|
c) |
On January 17, 2019, the Company's Board of Directors approved to grant options to purchase 201,828 ordinary shares to non-executive directors of the Company, with an exercise price of $3.97. The options will vest over 3 years in
twelve equal quarterly instalments starting in the vesting commencement date (as described in each agreement). The grant was subject to the approval by the shareholders' of the Company, which approved the grant in May 2019. The fair
value of the options at the date of grant was $531 thousand.
|
d) |
On August 5, 2019, the Company’s Board of Directors approved to grant options to purchase 696,587 ordinary shares to the new CEO, with an exercise price of $2.75 per share. The options vest over 4 years from the date of grant. 25%
will vest on the first anniversary of the date of grant and the remaining 75% options shall vest in twelve equal quarterly installments following the first anniversary of the grant date. The grant was subject to the approval by the
shareholders of the Company, which approved the grant in October 2019. The fair value of the options at the date of grant was $1,074 thousand.
|
2) |
Exercise of options
|
3) |
In July 2019, one of the Company’ shareholders' exercised his right to acquire 32,250 ordinary shares for a total consideration of $100 thousands (upon achievement of the second milestone) in accordance with its preferred share A
purchase agreement signed in 2014 and its following amendments.
|
4) |
On July 20, 2019, the 443,950 warrants to purchase 443,950 ordinary shares for a purchase price of $3.69 per share (upon achievement of the second milestone) in accordance with preferred share A purchase agreement signed in 2014 and
its following amendments have expired. Following the expiration, the Company classified $1,352 thousand from Other Reserves to Additional paid in Capital.
|
Nine months ended
|
Three months ended
|
|||||||||||||||
September 30
|
September 30
|
|||||||||||||||
2019
|
2018
|
2019
|
2018
|
|||||||||||||
U.S. dollars in thousand
(except for share numbers)
|
||||||||||||||||
Loss attributable to equity holders of the Company
|
7,355
|
7,659
|
2,994
|
5,066
|
||||||||||||
Less:
|
||||||||||||||||
Income from change in fair value of financial liabilities at fair value
|
-
|
135
|
-
|
-
|
||||||||||||
Loss used for the computation of diluted loss per share
|
7,355
|
7,794
|
2,994
|
5,066
|
||||||||||||
Weighted average number of Ordinary Shares used in the computation of basic loss per share
|
11,750,868
|
6,777,841
|
12,045,115
|
11,277,503
|
||||||||||||
Add:
|
||||||||||||||||
Weighted average number of additional shares issuable upon the assumed conversion/ exercise of:
|
||||||||||||||||
Warrants to issue preferred shares and shares
|
-
|
47,691
|
-
|
-
|
||||||||||||
-
|
47,691
|
-
|
-
|
|||||||||||||
Weighted average number of shares used in the computation of diluted loss per share
|
11,750,868
|
6,825,532
|
12,045,115
|
11,277,503
|
||||||||||||
Basic loss per Share
|
0.63
|
1.13
|
0.25
|
0.45
|
||||||||||||
Diluted loss per Share
|
0.63
|
1.14
|
0.25
|
0.45
|
a) |
On November 18, 2019, the Company’s Board of Directors approved options grants as follows:
|
i) |
An options grant to purchase 30,385 ordinary shares to the new US-based CFO, with an exercise price of $2.53 per share. The options will vest over two years in equal monthly installments following the grant date. The grant is
subject to the approval by the shareholders of the Company.
|
ii) |
An options grant to purchase 33,638 ordinary shares a non-executive director of the Company, with an exercise price of $2.53. The options will vest over 3 years in twelve equal quarterly instalments starting in the vesting
commencement date (as described in the agreement). The grant is subject to the approval by the shareholders of the Company.
|
b) |
On November 2019, The Board of Directors approved options grant to a services provider in accordance with business development and advisory services agreement. Under the terms of the agreement, the Company agreed to grant options
to purchase 62,393 ordinary shares at an exercise price of $2.53. The options will vest over six months in six equal monthly instalments starting in the effective date (as described in the agreement).
|
• |
our operation as a development stage company with limited operating history and a history of operating losses and our ability to fund our operations going forward;
|
• |
our ability to secure additional funding as may be needed, including, without limitation, to fund our ongoing operations and complete the clinical trials for our product development candidates.
|
• |
our recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern;
|
• |
our ability to develop and advance product candidates into, and successfully complete, clinical studies;
|
• |
uncertainty surrounding whether any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized, including that we will be able to demonstrate to regulators the noninferiority of
EB613 in comparison to Forteo as part of a 505(b)(2) submission or that we will be able to demonstrate to regulation the clinical superiority of EB612 over Natpara, which is required to overcome Natpara’s drug exclusivity;
|
• |
our competitive position, with respect to Natpara, our key competitor for hypoparathyroidism treatment, and certain injectable anabolic treatments such as Forteo®, or newer products recently launched for osteoporosis treatment;
|
• |
our ability to use and expand our drug delivery technology to other product candidates;
|
• |
our reliance on third parties to conduct our clinical trials and on third-party suppliers to supply or produce our product candidates; our being subject to ongoing regulatory obligations if our products secure regulatory approval;
|
• |
our ability to develop sales, marketing and distribution infrastructure;
|
• |
the pricing and reimbursement of our product candidates, if approved;
|
• |
our ability to achieve market acceptance for our product candidates;
|
• |
our ability to obtain and maintain adequate intellectual property rights and adequately protect and enforce such rights;
|
• |
our ability to retain key personnel and recruit additional qualified personnel;
|
• |
our expectations about cash use;
|
• |
our ability to manage growth; and
|
• |
other risk factors discussed under “Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2018.
|
(unaudited)
Nine Months Ended September 30, |
Increase (Decrease)
|
|||||||||||||||
2019
|
2018
|
$
|
%
|
|||||||||||||
(In thousands, except for percentage information)
|
||||||||||||||||
Revenues
|
$
|
(134
|
)
|
$
|
-
|
$
|
(134
|
)
|
100
|
% | ||||||
Cost of revenues
|
102
|
-
|
102
|
|
100
|
% | ||||||||||
Operating Expenses:
|
||||||||||||||||
Research and development, net
|
5,234
|
6,464
|
(1,230
|
)
|
(19
|
)%
|
||||||||||
General and administrative
|
2,757
|
1,914
|
843
|
|
44
|
% | ||||||||||
Operating loss
|
7,959
|
8,378
|
(419
|
)
|
(5
|
)%
|
||||||||||
Financial income, net
|
(604
|
)
|
(719
|
)
|
115
|
|
(16
|
)%
|
||||||||
Net loss
|
$
|
7,355
|
$
|
7,659
|
$
|
304
|
|
3.9
|
% |
(unaudited)
Three Months Ended September 30, |
Increase (Decrease)
|
|||||||||||||||
2019
|
2018
|
$
|
%
|
|||||||||||||
(In thousands, except for percentage information)
|
||||||||||||||||
Revenues
|
$
|
(60
|
)
|
$
|
(60
|
)
|
100
|
% | ||||||||
Cost of revenue
|
40
|
40
|
|
100
|
% | |||||||||||
Expenses:
|
||||||||||||||||
Research and development, net
|
1,786
|
$
|
1,806
|
$
|
(20
|
)
|
(1.1
|
)%
|
||||||||
General and administrative
|
1,073
|
1,060
|
13
|
|
1.2
|
% |
||||||||||
Operating loss
|
2,839
|
2,866
|
(27
|
)
|
(0.9
|
)%
|
||||||||||
Financial expenses , net
|
155
|
2,200
|
(2,045
|
)
|
(93
|
)%
|
||||||||||
Net loss
|
$
|
2,994
|
$
|
5,066
|
$
|
(2,072
|
)
|
(40.9
|
)%
|
• |
Enrollment Continues for Phase 2 study for oral PTH in Osteoporosis; Top-line 3-month Biomarker Data expected in mid 2020
|
• |
Presented Positive Results of a Phase 2 PK/PD study in Hypoparathyroidism patients.
|
• |
Conference call and live webcast today at 8:30 am Eastern Time
|
• |
Full patient enrollment to be completed by the end of the first quarter of 2020
|
• |
Top-line data from the interim (50%) 3-month biomarker endpoint in the second quarter of 2020
|
• |
Top-line data from the full 3-month biomarker endpoint in the third quarter of 2020
|
• |
Bone mineral density data at 6 months are expected to be completed in fourth quarter 2020
|
◾ |
Oral hPTH(1-34) 2.25 mg QID for one day is associated with an increase in serum albumin-corrected calcium and 1,25(OH)2D (1,25-dihydroxyvitamin D), a decrease in serum phosphate, and a decrease in urinary calcium in
patients with hypoparathyroidism. The patients also received calcium supplements and either alfacalcidol or calcitriol.
|
◾ |
Oral PTH produced similar biological effects to Natpara® 100 µg QD, the highest dose of hPTH (1-84) currently indicated for use in patients with hypoparathyroidism, on serum calcium, phosphate and Vit D. Additionally, Oral
hPTH (1-34) effected a decrease in urinary calcium. These changes in serum PD parameters were sustained over the 24-hour period of observation from time zero.
|
◾ |
BID, TID and QID regimens showed a dose-dependent increase in 1,25(OH)2D indicating that the long-term treatment, even with the less frequent regimens, may be an effective treatment option for those patients suffering from
less severe hypoparathyroidism.
|
◾ |
Treatment with Oral hPTH (1-34) dosed at multiple times during the day has the potential to reduce calciuria generally associated with maintenance of serum calcium within the normal range using calcium supplements and calcitriol
analogs alone.
|
◾ |
There were no treatment-emergent adverse events of hypercalcemia, as well as no treatment-emergent Serious Adverse Events reported in the study.
|
From the US:
|
1 855 547-3865
|
International:
|
1 409 217-8787
|
From Israel:
|
1 809 315 362
|
Conference ID:
|
3677455
|
Webcast:
|
https://edge.media-server.com/mmc/p/i5yx6yjw
|
Entera Bio Ltd.
Adam Gridley, CEO
Tel: +972-2-532-7151
adam@enterabio.com
|
September 30
|
December 31
|
|||||||
2019
|
2018
|
|||||||
U.S. dollars in thousands
|
||||||||
Assets
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
5,907
|
7,506
|
||||||
Short-term bank deposits
|
-
|
4,015
|
||||||
Accounts receivable
|
-
|
725
|
||||||
Other current assets
|
297
|
220
|
||||||
TOTAL CURRENT ASSETS
|
6,204
|
12,466
|
||||||
NON-CURRENT ASSETS:
|
||||||||
Property and equipment
|
217
|
224
|
||||||
Right to use assets
|
295
|
-
|
||||||
Intangible assets
|
607
|
651
|
||||||
TOTAL NON-CURRENT ASSETS
|
1,119
|
875
|
||||||
TOTAL ASSETS
|
7,323
|
13,341
|
||||||
Liabilities and shareholders' equity
|
||||||||
CURRENT LIABILITIES:
|
||||||||
Accounts payable:
|
||||||||
Trade
|
594
|
473
|
||||||
Other
|
1,501
|
1,090
|
||||||
Lease liabilities
|
156
|
-
|
||||||
Contract liabilities
|
91
|
225
|
||||||
TOTAL CURRENT LIABILITIES
|
2,342
|
1,788
|
||||||
NON-CURRENT LIABILITIES:
|
||||||||
Warrants to purchase ordinary shares
|
700
|
1,372
|
||||||
Lease liabilities
|
173
|
-
|
||||||
Severance pay obligations, net
|
70
|
65
|
||||||
TOTAL NON-CURRENT LIABILITIES
|
943
|
1,437
|
||||||
TOTAL LIABILITIES
|
3,285
|
3,225
|
||||||
COMMITMENTS AND CONTINGENCIES
|
||||||||
SHAREHOLDERS' EQUITY:
|
||||||||
Ordinary Shares, NIS 0.0000769 par value:
|
||||||||
Authorized - as of September 30, 2019 and December 31, 2018, 140,010,000 shares; issued and outstanding: as of September 30, 2019, and December 31, 2018 – 12,153,980
shares and 11,459,780 shares, respectively.
|
*
|
*
|
||||||
Accumulated other comprehensive income
|
41
|
41
|
||||||
Other reserves
|
11,912
|
13,019
|
||||||
Additional paid in capital
|
51,557
|
49,173
|
||||||
Accumulated deficit
|
(59,472
|
)
|
(52,117
|
)
|
||||
TOTAL SHAREHOLDERS' EQUITY
|
4,038
|
10,116
|
||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
|
7,323
|
13,341
|
Nine months ended
|
Three months ended
|
|||||||||||||||
September 30
|
September 30
|
|||||||||||||||
2019
|
2018
|
2019
|
2018
|
|||||||||||||
U.S. dollars in thousands
|
||||||||||||||||
REVENUE
|
(134
|
)
|
-
|
(60
|
)
|
-
|
||||||||||
COST OF REVENUE
|
102
|
-
|
40
|
-
|
||||||||||||
RESEARCH AND DEVELOPMENT EXPENSES, NET
|
5,234
|
6,464
|
1,786
|
1,806
|
||||||||||||
GENERAL AND ADMINISTRATIVE EXPENSES
|
2,757
|
1,914
|
1,073
|
1,060
|
||||||||||||
OPERATING LOSS
|
7,959
|
8,378
|
2,839
|
2,866
|
||||||||||||
FINANCIAL EXPENSES (INCOME):
|
||||||||||||||||
Loss (income) from change in fair value of financial
liabilities at fair value |
(672
|
)
|
(719
|
)
|
122
|
2,177
|
||||||||||
Other financial expenses , net
|
68
|
-
|
33
|
23
|
||||||||||||
FINANCIAL EXPENSES (INCOME), net
|
(604
|
)
|
(719
|
)
|
155
|
2,200
|
||||||||||
NET COMPREHENSIVE LOSS FOR THE PERIOD
|
7,355
|
7,659
|
2,994
|
5,066
|
U.S. dollars
|
U.S. dollars
|
|||||||||||||||
LOSS PER ORDINARY SHARE:
|
||||||||||||||||
Basic
|
0.63
|
1.13
|
0.25
|
0.45
|
||||||||||||
Diluted
|
0.63
|
1.14
|
0.25
|
0.45
|
||||||||||||
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:
|
||||||||||||||||
Basic
|
11,750,868
|
6,777,841
|
12,045,115
|
11,277,503
|
||||||||||||
Diluted
|
11,750,868
|
6,825,532
|
12,045,115
|
11,277,503
|